Asthma Biologic Denied by Insurance: Appeal Guide
Severe asthma biologic denied? Learn how to appeal using eosinophil counts, IgE levels, and GINA guidelines for Dupixent, Fasenra, Nucala, or Tezspire.
Severe, uncontrolled asthma is a life-threatening condition that causes frequent exacerbations, emergency department visits, hospitalizations, and dramatically reduced quality of life. For patients with severe asthma that remains uncontrolled despite high-dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA), biologic therapies offer targeted relief — including dupilumab (Dupixent), benralizumab (Fasenra), mepolizumab (Nucala), reslizumab (Cinqair), and tezepelumab (Tezspire). Insurance denials for these biologics are common and leave patients in danger. Fortunately, they can be appealed effectively.
Why Insurers Deny Asthma Biologics
Biomarker thresholds not met. Most asthma biologics target specific inflammatory pathways and have biomarker eligibility criteria. Anti-IL-5 agents (mepolizumab, benralizumab, reslizumab) require blood eosinophil counts ≥150–300 cells/µL. Omalizumab (Xolair) requires elevated IgE levels and confirmed allergen sensitization. Plans use these as gatekeeping criteria, denying if the required lab values aren't documented.
Inadequate documentation of "uncontrolled severe asthma." Insurers want to see that asthma is truly uncontrolled — documented with spirometry (FEV1), asthma control questionnaire scores (ACQ, ACT), number of exacerbations in the past year, and number of oral steroid courses.
Failure to complete step therapy. Prior to a biologic, insurers typically require documented use of high-dose ICS + LABA at maximum doses, and often add-on controllers like leukotriene receptor antagonists (montelukast) or long-acting muscarinic antagonists (tiotropium).
Wrong biologic selected. If a patient's biomarkers match one approved biologic and the prescriber requests another, the insurer may deny. (Tezspire is approved regardless of biomarker profile — this should be cited for patients who don't meet eosinophil criteria for other agents.)
Building Your Clinical Appeal
Document Biomarker Eligibility
Request lab results showing blood eosinophil count (for anti-IL-5 agents) or serum IgE with skin prick test or RAST results (for omalizumab). For dupilumab, the FDA label requires a blood eosinophil count ≥150 cells/µL or oral corticosteroid-dependent asthma. For tezspire, no biomarker threshold is required — this is a key advantage for patients who don't qualify for other biologics.
Ensure your appeal includes the specific biomarker values from lab reports dated within the approved window (often within 12 months).
Quantify Exacerbations and OCS Use
Document the number of asthma exacerbations in the prior 12 months — defined as worsening requiring a burst of oral corticosteroids, an emergency department visit, or hospitalization. Most payer criteria require 2 or more exacerbations in the past year. Include dates, treatment received, and emergency or hospital records.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Oral corticosteroid (OCS) dependence — requiring daily or near-daily prednisone — is itself a strong argument, as prolonged OCS use causes serious harm (diabetes, osteoporosis, Cushing's syndrome, adrenal suppression). Biologics are demonstrated OCS-sparing agents.
Confirm High-Dose ICS/LABA Use
Document current controller therapy: ICS (fluticasone, budesonide, beclomethasone) at high doses per GINA guidelines, LABA (salmeterol, formoterol), and any additional controllers tried. Include prescription records and doses. If medications were tried and discontinued due to side effects or inadequate response, note this.
Pulmonary Function Testing
Submit spirometry results showing reduced FEV1 (ideally pre- and post-bronchodilator) and reduced FEV1/FVC ratio, with limited reversibility. Residual airflow obstruction despite optimal controller therapy supports medical necessity.
Cite GINA Guidelines
The Global Initiative for Asthma (GINA) 2024 guidelines recommend biologic therapy as Step 5 treatment for patients with severe, uncontrolled asthma despite high-dose ICS/LABA. GINA endorses phenotyping with biomarkers to guide biologic selection. Your pulmonologist or allergist should cite GINA guidelines in the letter of medical necessity and attest that your case meets Step 5 criteria.
Include Asthma Control Scores
The Asthma Control Test (ACT, max 25) and Asthma Control Questionnaire (ACQ) are validated tools. An ACT score ≤19 indicates poorly controlled asthma. Include these in your appeal — they provide objective, validated evidence of uncontrolled disease.
Urgency Argument
Severe, uncontrolled asthma can be fatal. Status asthmaticus and near-fatal asthma attacks are life-threatening emergencies. If your patient has had hospitalizations, ICU admissions, or near-fatal attacks, document these prominently. The cost of repeated emergency and hospital care exceeds the cost of biologic therapy — and the human cost of preventable asthma attacks is inestimable.
Resources
- Asthma and Allergy Foundation of America (AAFA) (aafa.org) — insurance navigation guides, patient advocacy
- American Academy of Allergy, Asthma & Immunology (AAAAI) — physician resources and clinical practice parameters
- Manufacturer patient support programs: AstraZeneca (Fasenra), GSK (Nucala), Sanofi/Regeneron (Dupixent MyWay), AstraZeneca (Tezspire), Genentech (Xolair Patient Support) all provide copay assistance, free drug during appeals, and benefits investigation support
Severe asthma biologics are among the most clinically compelling cases for appeal — the biomarker documentation and exacerbation history build an airtight case when organized correctly.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides